Equally contributing first authors.
Copeptin and risk stratification in patients with ischemic stroke and transient ischemic attack: The CoRisk Study
Article first published online: 15 FEB 2012
© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization
International Journal of Stroke
Volume 8, Issue 3, pages 214–218, April 2013
How to Cite
De Marchis, G. M., Katan, M., Weck, A., Brekenfeld, C., Mattle, H. P., Buhl, D., Müller, B., Christ-Crain, M. and Arnold, M. (2013), Copeptin and risk stratification in patients with ischemic stroke and transient ischemic attack: The CoRisk Study. International Journal of Stroke, 8: 214–218. doi: 10.1111/j.1747-4949.2011.00762.x
This study is registered in ClinicalTrials.gov under the number NCT00878813.
Conflict of interest: MK, MCC, BM, and PS received support from Thermo Fisher Scientific to attend meetings and fulfilled speaking engagements not related to the CoRisk study. BM serves as a consultant and receives research support from Thermo Fisher Scientific not related o this study. All other authors have no financial disclosure related to the present manuscript.
Funding: The study was supported by an unrestricted research grant of: B•R•A•H•M•S Biomarkers Clinical Diagnostics Division, Thermo Fisher Scientific, Neuendorfstr. 25;16761 Hennigsdorf-Berlin Germany; Foundation of the Inselspital Bern (Switzerland); Foundation Scientia et Arte, Bern (Switzerland); De Quervain's Grant for young clinical investigators, Clinical Trials Unit, Bern (Switzerland) to GMDM. Career Development Grant from the Swiss National Science Foundation (SNF) to MK. All supporting entities will have no role in the collection, management, analysis, and interpretation of the data; or the preparation, or approval of the manuscript.
- Issue published online: 15 MAR 2013
- Article first published online: 15 FEB 2012
- Foundation of the Inselspital Bern (Switzerland)
- Foundation Scientia et Arte, Bern (Switzerland)
- Clinical Trials Unit, Bern (Switzerland)
- Swiss National Science Foundation (SNF)
- risk stratification;
Copeptin independently predicts functional outcome and mortality at 90 days and one-year after ischemic stroke. In patients with transient ischemic attack, elevated copeptin values indicate an increased risk of further cerebrovascular events.
The Copeptin Risk Stratification (CoRisk) study aims to validate the predictive value of copeptin in patients with ischemic stroke and transient ischemic attack. In patients with ischemic stroke, the CoRisk study aims to further explore the effect of treatment (i.e. thrombolysis) on the predictive value of copeptin.
Prospective observational multicenter study analyzing three groups of patients, i.e. patients with ischemic stroke treated with and without thrombolysis and patients with transient ischemic attack.
Primary end-point: In patients with ischemic stroke, the primary end-point includes disability (modified Rankin scale from 3 to 5) and mortality (modified Rankin scale 6) at three-months after stroke. In patients with transient ischemic attack, the primary end-point is a recurrent ischemic cerebrovascular event (i.e. ischemic stroke or recurrent transient ischemic attack). Secondary end-point: In patients with ischemic stroke, the secondary end-points include in-house complications (i.e. symptomatic intracerebral hemorrhage, malignant edema, aspiration pneumonia or seizures during hospitalization, and in-house mortality).